ARS Pharmaceuticals Inc (SPRY) stock saw a decline, ending the day at $14.77 which represents a decrease of $-0.09 or -0.61% from the prior close of $14.86. The stock opened at $14.97 and touched a ...

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...

ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need ...

圣地亚哥 - 生物制药公司ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)宣布,其处方药neffy®(肾上腺素鼻喷剂)现已在全美上市。美国食品药品监督管理局(FDA)上月批准了用于治疗体重超过30公斤(66磅)个体I型过敏反应(包括过敏性休克)的2毫克neffy。 通过neffyConnect项目和与在线药房BlinkRx的合作,符合条件的商业保险患者可以25美元的 ...

ARS Pharmaceuticals Inc (SPRY) stock saw a modest uptick, ending the day at $14.05 which represents a slight increase of $1.00 or 7.66% from the prior close of $13.05. The stock opened at $13.1 and ...

坎托菲茨杰拉德公司：重申ARS Pharmaceuticals(SPRY.US)评级，由增持调整至增持评级, 目标价由30.00美元调整至30.00美元。 ARS Pharmaceuticals（SPRY.US）公司简介 ...

Leerink Partners：维持ARS Pharmaceuticals(SPRY.US)评级，由优于大市调整至优于大市评级, 目标价由21.00美元调整至25.00美元。 ARS Pharmaceuticals（SPRY.US）公司 ...

ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Credit: ARS Pharmaceuticals. Neffy is indicated for adult and pediatric patients weighing at least 30kg. It is recommended that patients be prescribed and have immediate access to 2 neffy nasal sprays ...

SAN DIEGO - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)已提交一份补充新药申请(sNDA),用于neffy® 1 mg,这是一种针对体重15至30公斤(33-66磅)儿童的无针式肾上腺素治疗,用于I型过敏反应,包括过敏性休克。此次提交是在FDA于2024年8月9日批准用于30公斤或以上患者的neffy 2 mg之后进行的。 该公司报告称,neffy ...